JPMorgan Chase & Co. Grows Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

JPMorgan Chase & Co. lifted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 123.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 189,295 shares of the biopharmaceutical company's stock after buying an additional 104,650 shares during the period. JPMorgan Chase & Co. owned approximately 0.12% of Ocular Therapeutix worth $1,617,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in Ocular Therapeutix during the 4th quarter valued at approximately $1,722,000. Charles Schwab Investment Management Inc. increased its stake in shares of Ocular Therapeutix by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock valued at $9,663,000 after buying an additional 21,025 shares during the period. Barclays PLC lifted its stake in Ocular Therapeutix by 37.1% in the third quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock worth $4,451,000 after acquiring an additional 138,441 shares during the period. RoundAngle Advisors LLC bought a new stake in Ocular Therapeutix in the fourth quarter valued at $1,695,000. Finally, Rosalind Advisors Inc. increased its position in Ocular Therapeutix by 27.5% during the 4th quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after purchasing an additional 243,700 shares during the period. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Ocular Therapeutix

In related news, insider Donald Notman sold 6,301 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the sale, the insider now directly owns 204,563 shares in the company, valued at approximately $1,603,773.92. The trade was a 2.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the transaction, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock worth $283,772 over the last quarter. 3.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. JMP Securities set a $19.00 target price on Ocular Therapeutix in a report on Tuesday, March 4th. William Blair began coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an "outperform" rating for the company. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada initiated coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Ocular Therapeutix has an average rating of "Moderate Buy" and a consensus price target of $16.38.

Ocular Therapeutix Stock Up 0.4 %

Ocular Therapeutix stock traded up $0.03 during mid-day trading on Thursday, hitting $8.33. The company had a trading volume of 73,240 shares, compared to its average volume of 1,458,146. Ocular Therapeutix, Inc. has a 12 month low of $4.79 and a 12 month high of $11.78. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock's 50 day moving average price is $7.32 and its two-hundred day moving average price is $8.45. The company has a market capitalization of $1.32 billion, a PE ratio of -6.31 and a beta of 1.49.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The firm had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. As a group, sell-side analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.